A Randomized Trial of Recruitment Strategies for Research Participation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02697799 |
Recruitment Status :
Completed
First Posted : March 3, 2016
Last Update Posted : October 23, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
This Study Will Focus on Recruitment Strategies and Attitudes Towards Research Among Patients Considering Participation in 2 Parent Randomized Controlled Trials Cancer Research Ethics | Behavioral: High-level recruitment strategy consent form Behavioral: Mid-level recruitment strategy consent form | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1296 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
Primary Purpose: | Health Services Research |
Official Title: | A Randomized Trial of Recruitment Strategies for Research Participation |
Study Start Date : | August 2016 |
Actual Primary Completion Date : | August 31, 2019 |
Actual Study Completion Date : | August 31, 2019 |
Arm | Intervention/treatment |
---|---|
Experimental: High-level recruitment strategy
Subjects in this group will receive pre-consent messaging and a consent form with a high-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
|
Behavioral: High-level recruitment strategy consent form
Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy |
Experimental: Mid-level recruitment strategy
Subjects in this group will receive pre-consent messaging and a consent form with a mid-level recruitment strategy for research participation in the parent study. The consent form will provide information on the first page, under the header that describes the purpose of the study, as well as in the consent sections describing the cost to participate in the study.
|
Behavioral: Mid-level recruitment strategy consent form
Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy |
No Intervention: No modified recruitment strategy
Subjects in this group will receive consent form without a modified recruitment strategy for research participation in the parent study.
|
- The primary outcome is the proportion of people assigned to each recruitment strategy that consent to participate in the three parent RCTs. [ Time Frame: Immediate- Several Days ]
- Attitudes towards research [ Time Frame: Immediate ]Attitudes towards research will be measured using the Research Attitudes Questionnaire-7 (RAQ-7). Originally designed with 11 items, a shorter 7-item version (RAQ-7) has been shown to have improved internal consistency and factorial validity.
- Attention to informed consent [ Time Frame: Immediate ]We will assess the amount of time patients spend reading each part of the parent RCT consent forms. On-site research coordinators will facilitate the collection of this data as patients read the document via the recruitment strategy study's electronic database.
- Perceived risks of the research [ Time Frame: Immediate ]Perceived risks of the research will be measured by the 9-item compared riskiness scale, which assesses perceptions of research risk. Using this approach, patients compare their assessment of the riskiness of the RCTs to other salient and more commonly encountered risks. Such comparative assessments have been shown to be less susceptible to errors in scale calibration than isolated ratings of risks.
- Incidence of therapeutic misconceptions [ Time Frame: Immediate ]We will assess patients' ability to distinguish research from individualized patient care by measuring rates of therapeutic misconception across recruitment strategies among patients considering participation in the parent RCTs. We will assess this outcome with a 4-item tool developed by Dr. Scott Kim, which has been used for similar purposes in several research contexts.
- Understanding of the trial [ Time Frame: Immediate ]To assess whether increased attention translates into improved understanding of the parent RCTs, we will use a 6-item Trial Elements Quiz, featuring core elements of the parent RCTs' consent form.
- Perceptions of influence or coercion [ Time Frame: Immediate ]To measure general perception of coercion and voluntariness of research participation, we will use the five-item Perceived Coercion Scale of the MacArthur Admission Experience Survey. The true/false scale is tailored to measure patients' perceptions of coercion in the inpatient psychiatric treatment admission process; we have edited the wording to make it relevant to participation in the parent RCTs.
- Retention through the end of treatment sessions [ Time Frame: 8 - 27 weeks ]We will assess the impact of the recruitment strategies on retention status in the protocol of the parent RCTs.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eligible for parent RCT
- 18 years or older
- No prior knowledge of recruitment strategies used for this trial
- Speaks English
Exclusion Criteria:
1)Prior knowledge of recruitment strategies used for this trial

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02697799
United States, Illinois | |
Northwestern University - Feinberg School of Medicine | |
Chicago, Illinois, United States, 60611 | |
United States, Massachusetts | |
Massachusetts General Hospital | |
Boston, Massachusetts, United States, 02114 | |
United States, Missouri | |
Washington University Siteman Cancer Center | |
Saint Louis, Missouri, United States, 63108 | |
United States, Pennsylvania | |
The Hospital of the University of Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 | |
The Perelman Center for Advanced Medicine | |
Philadelphia, Pennsylvania, United States, 19104 | |
University of Pennsylvania | |
Philadelphia, Pennsylvania, United States, 19104 | |
United States, Texas | |
The University of Texas, MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Scott D Halpern, MD, PhD | University of Pennsylvania |
Responsible Party: | Scott Halpern, Associate Professor of Medicine, University of Pennsylvania |
ClinicalTrials.gov Identifier: | NCT02697799 |
Other Study ID Numbers: |
823491 |
First Posted: | March 3, 2016 Key Record Dates |
Last Update Posted: | October 23, 2020 |
Last Verified: | October 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |